Business Wire

CA-NETAPP

Share
NetApp and Cisco Strengthen Partnership Announcing New FlexPod XCS to Extend Converged Infrastructure into the Hybrid Cloud

NetApp (NASDAQ: NTAP), a global, cloud-led, data-centric software company, together with Cisco (NASDAQ: CSCO), today announced the evolution of FlexPod with the introduction of FlexPod® XCS, providing one automated platform for modern applications, data and hybrid cloud services.

FlexPod is composed of pre-validated storage, networking, server technologies from Cisco and NetApp. The new FlexPod XCS platform is designed to accelerate the delivery of modern applications and data in a hybrid cloud environment. FlexPod XCS is the first and only hybrid cloud solution natively integrated across all three major public cloud providers. Additionally, organizations will have the option to use FlexPod-as-a-Service, a pay-as-you-grow pricing model for financial and operational flexibility.

“For years, FlexPod has been helping Presidio customers increase app performance, save software Capex, and decrease unplanned downtime incidents,” said Raphael Meyerowitz, vice president, Engineering at Presidio. “With FlexPod XCS, NetApp and Cisco are providing more flexibility, accessibility and scalability to our customers to deliver a seamless hybrid cloud experience.”

“It is great seeing Cisco and NetApp launching FlexPod XCS together in this hybrid cloud era,” said Jeffrey den Oudsten, Chief Technology Officer at Conscia Netherlands. “Standardization on FlexPod XCS brings rich technologies and huge benefits for us and our customers in various ways, with ability to deliver one point for billing, ordering, support and validated designs. Conscia is determined to facilitate the best hybrid cloud infrastructure for its customers, and together with Cisco and NetApp, we have the best-in-class technology partners helping us to deliver on that promise.”

FlexPod XCS simplifies hybrid cloud operations by increasing accessibility and scalability, extending the infrastructure from an on-premises and edge standard to the hybrid cloud. This new offering lays the groundwork for continued joint innovation that will bring new solutions to market for hybrid cloud, containers, and modern workloads.

FlexPod XCS provides a new set of capabilities to the FlexPod platform:

  • Hybrid Cloud Connectivity: By extending organizations’ data fabric, customers gain the operational certainty of putting the right apps and data in the right place at the right time.
  • Automation: Comprehensive infrastructure automation across all lifecycle phases using Cisco Intersight™ Cloud Orchestrator and NetApp automated scripts and workflows to simplify day-to-day IT operations including configuration, deployment, expansion, and infrastructure consumption and optimization.
  • Visibility: Providing an enhanced and unified view of all FlexPod components through Cisco Intersight, enabling organizations to respond to their business needs more quickly with more intelligent resource decisions
  • FlexPod-as-a-Service: Lowering initial costs for flexibility and tailoring purchasing options based on budgets and usage
  • New Reference Architecture with NetApp Cloud Volumes ONTAP ® (CVO) instances in AWS: FlexPod XCS and ONTAP integration with automation via Cisco Intersight

FlexPod XCS also allows IT departments to gain new insights with full-stack visibility and customized automation capabilities that increase operational productivity. The new FlexPod-as-a-Service consumption model enables customers to have more financial and operational flexibility by aligning costs based on usage.

"Our strategic relationship with NetApp continues to create value for businesses through deep technology integration aimed at solving our customers' biggest challenges,” said Siva Sivakumar, Vice President, Cloud & Compute Product Management, Cisco. “FlexPod XCS powered by Cisco Intersight delivers key new capabilities for our customers such as automation, visibility and hybrid cloud operations into a single unified platform for modern apps, data, and hybrid cloud services.”

“We are proud of our continued innovation with Cisco as we expand FlexPod’s capabilities that solve for organizations’ unique business challenges,” said Mike Arterbury, Vice President, Hybrid Cloud Infrastructure & OEM Solutions at NetApp. “Building on our twelve-year partnership with Cisco, FlexPod XCS combines our best-in-class technologies to simplify the delivery of data and applications, enabling enterprises to run new services more efficiently at the edge, core or in the cloud.”

FlexPod® XCS is in preview for partners and customers and is expected to be generally available globally in mid-2022.

Additional Resources:

About FlexPod

Trusted by thousands of customers across the globe, the enhanced FlexPod XCS platform brings a new level of visibility and automation that can help propel customers’ journey into hybrid cloud operations.​ Composed of prevalidated storage, networking and server technologies, and management software, FlexPod® XCS is designed to increase IT responsiveness to organizational needs providing intelligent insights to optimize costs and performance, support deployment decisions with cloud-like consumption models, and maintain existing configurations across FlexPod infrastructure. By simplifying the delivery of data and applications, enterprises have an advantage of running new services and workloads at the edge, core, or in the cloud.

FlexPod® XCS pricing is mapped to Cisco Intersight Advantage and Premier Tiers and current FlexPod pricing.

About NetApp

NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

Many of the products and features described herein remain in varying stages of development and will be offered on a when-and-if-available basis. The delivery timeline of these products and features is subject to change at the sole discretion of Cisco or NetApp, and neither Cisco nor NetApp will have liability for delay in the delivery or failure to deliver any of the products or features set forth in this document.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye